Target intelligence / Profile preview

Hemagglutinin head domain of Influenza A virus (HA head domain)

Target
HA head domain
Molecular classification
Viral glycoprotein, Receptor-binding domain, Class I viral fusion protein (head subdomain), Other
01

Overview

The **hemagglutinin head domain of Influenza A virus** is the globular portion of the trimeric hemagglutinin (HA) glycoprotein found at the apex of each HA monomer. It harbors the receptor-binding site responsible for recognizing sialic acid moieties on host epithelial cells, thereby facilitating viral attachment and entry. This domain is the principal target of neutralizing antibodies generated by natural infection and vaccination, but also exhibits high antigenic variability, driving the need for frequent vaccine updates and enabling immune escape. Broadly neutralizing antibodies that target conserved epitopes on or near the head domain are under research as universal influenza therapeutics. Targeting the head domain remains central to influenza control strategies, but its variability poses major clinical and research challenges[1][3][4][5].

Other names
Hemagglutinin globular head domainHA headInfluenza A hemagglutinin receptor-binding domainInfluenza A virus HA head
02

Mechanism of action

Inhibition of receptor binding through antibody occupancy of the head domain, blocking viral attachment - Inhibition of conformational changes required for membrane fusion

03

Biological functions

Receptor binding to host cell sialic acidInitiation of viral entryMajor antigenic determinant for neutralizing antibody responseTarget for vaccine and antiviral development
04

Disease associations

Infection (Influenza A virus diseases)
05

Safety considerations

Antigenic drift and shift: high sequence variability in the head domain can lead to immune escape and decreased vaccine effectivenessPotential selection of viral escape mutants under monoclonal antibody therapy
06

Interacting drugs

Monoclonal antibodies against HA (e.g., broadly neutralizing antibodies such as C05, CR6261)

1 more in the full profile.

07

Biomarkers

Antibody titers against HA head domain (hemagglutination inhibition titers, used in vaccine efficacy and exposure assessment)

Beyond the preview

Go deeper on Hemagglutinin head domain of Influenza A virus (HA head domain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemagglutinin head domain of Influenza A virus (HA head domain).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call